NK Cell Therapy Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight | Artiva Biotherapeutics, Glycostem, Fate Therapeutics, Indapta Therapeutics, Senti Biosciences

DelveInsight's "NK Cell Therapy Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the NK Cell Therapy, historical and forecasted epidemiology as well as the NK Cells therapeutics market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover which therapies are expected to grab the NK Cell Therapy Market Share @ NK Cell Therapy Market Outlook- https://www.delveinsight.com/sample-request/nk-cell-therapy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the NK Cell Therapy Market Report
• In February 2025, Precision Biotech Taiwan Corporation announced a phase Ι & IIa, Open-label Study to Evaluate Safety and Efficacy of the Combination Therapy of Allogeneic PB103 and Standard Cancer Treatment in the IIIB/IV or Recurrent Non-small Cell Lung Cancer (NSCLC) Patients.
• The SEER database estimates that approximately 35,730 individuals (19,860 men and 15,870 women) were diagnosed with multiple myeloma in the United States in 2023, representing about 1.8% of all new cancer cases nationwide.
• Acute Myeloid Leukemia is among the most common types of leukemia in adults, though it remains relatively rare, comprising about 1% of all cancer cases. AML is slightly more prevalent in men than in women, but the average lifetime risk of developing AML for both genders is approximately 0.5%. According to DelveInsight's analysis, there were an estimated 30,000 new cases of multiple myeloma in the United States in 2023, with numbers projected to rise during the forecast period.
• The American Cancer Society's 2024 projections indicate that approximately 20,800 new cases of acute myeloid leukemia are anticipated in the United States, with the majority occurring in adults.
• The leading NK Cell Therapy Companies such as Artiva Biotherapeutics, Glycostem, Fate Therapeutics, Indapta Therapeutics, Senti Biosciences, and others.
• Promising NK Cell Therapy Pipeline Therapies such as AlloNK, oNKord, FT522, IDP-023, SENTI-202, and others.

Stay ahead in the NK Cell Therapy Therapeutics Market with DelveInsight's Strategic Report @ NK Cell Therapy Market Outlook- https://www.delveinsight.com/sample-request/nk-cell-therapy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

NK Cell Therapy Epidemiology Segmentation in the 7MM
• Total Incident Cases of Selected Indications for NK Cell Therapy
• Total Eligible Patient Pool for NK Cell Therapy in Selected Indications
• Total Treated Cases in Selected Indications for NK Cell Therapy

Download the report to understand which factors are driving NK Cell Therapy Epidemiology trends @ NK Cell Therapy Prevalence- https://www.delveinsight.com/sample-request/nk-cell-therapy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

NK Cell Therapy Emerging Drugs
• AlloNK: Artiva Biotherapeutics
AlloNK (also known as AB-101) is a cryopreserved, allogeneic NK (NK) cell therapy candidate that is not genetically modified. It is designed to enhance the effectiveness of B-cell-targeting monoclonal antibodies, promoting B-cell depletion. Developed as an off-the-shelf therapy, AlloNK is intended for use in combination with monoclonal antibodies and can be administered in community healthcare settings. Currently, a Phase I/II clinical trial is evaluating the combination of AlloNK and rituximab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

• oNKord: Glycostem
Glycostem develops innovative treatment options for hematological conditions and solid tumors through its first-generation NK cell-based immunotherapy, oNKord. This therapy received orphan drug designation for acute myeloid leukemia (AML) from the EMA in 2014 and the FDA in 2016. Currently, oNKord is undergoing evaluation in a Phase I/IIa clinical trial for the treatment of AML.

• FT522: Fate Therapeutics
FT522 is an innovative off-the-shelf CAR NK cell therapy designed to target and eliminate multiple pathogenic cell types, addressing systemic autoimmunity without the need for patient lympho-conditioning. Currently, it is being assessed in a Phase I clinical trial for relapsed/refractory B-cell lymphoma. Additionally, the company intends to broaden the clinical development of the FT522 program to include autoimmune diseases.

NK Cell Therapy Market Dynamics
The NK cell therapy market is experiencing significant momentum as it emerges as a promising avenue in cancer immunotherapy and other disease treatments. FT522, an off-the-shelf cell therapy, offers a unique therapeutic approach for autoimmune diseases by targeting CD19+ B cells and other pathogenic cell types without the need for conditioning chemotherapy.

To learn more about NK Cell Therapy treatment guidelines, visit @ NK Cell Therapy Treatment Market Landscape- https://www.delveinsight.com/sample-request/nk-cell-therapy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

NK Cell Therapy Companies
Artiva Biotherapeutics, Glycostem, Fate Therapeutics, Indapta Therapeutics, Senti Biosciences, and others.

NK Cell Therapy Treatment Market
Natural killer (NK) cells exist in multiple subsets, and their functions can vary across different organs due to their dynamic nature. Harnessing their cytotoxic potential through therapeutic approaches like adoptive NK cell therapy and bispecific killer cell engagers (BiKEs) holds significant promise. While adoptive NK cell therapy offers a favorable safety profile, improving combination strategies by gaining deeper insights into NK cell-specific mechanisms could enhance therapeutic outcomes. For instance, integrating cytokine-induced memory-like NK cells with chimeric antigen receptor (CAR) or BiKE expression has demonstrated enhanced responses. NK cells present immense potential as innovative therapeutic agents against various diseases, including HER2-positive solid tumors, B-cell lymphoma, acute myeloid leukemia, and more.

Learn more about the FDA-approved drugs for NK Cell Therapy @ Drugs for NK Cell Therapy Treatment- https://www.delveinsight.com/sample-request/nk-cell-therapy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the NK Cell Therapy Market Report
• Coverage- 7MM
• Study Period 2020-2034
• NK Cell Therapy Companies- Artiva Biotherapeutics, Glycostem, Fate Therapeutics, Indapta Therapeutics, Senti Biosciences, and others.
• NK Cell Therapy Pipeline Therapies- AlloNK, oNKord, FT522, IDP-023, SENTI-202, and others.
• NK Cell Therapy Market Dynamics: Emerging NK Cell Therapy Drugs
• NK Cell Therapy Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• NK Cell Therapy Unmet Needs, KOL's views, Analyst's views, NK Cell Therapy Market Access and Reimbursement

Discover more about NK Cell Therapy Drugs in development @ NK Cell Therapy Clinical Trials Assessment- https://www.delveinsight.com/sample-request/nk-cell-therapy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. NK Cell Therapy Executive Summary
3. Competitive Intelligence Analysis for NK Cell Therapy
4. NK Cell Therapy: Market Overview at a Glance
5. NK Cell Therapy: Disease Background and Overview
6. Natural Killer Cell Therapy Patient Journey
7. NK Cell Therapy Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Natural Killer Cell Therapy Unmet Needs
10. Key Endpoints of NK Cell Therapy Treatment
11. Natural Killer Cell Therapy Marketed Products
12. Natural Killer Cell Therapy Emerging Therapies
13. NK Cell Therapy: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of NK Cell Therapy
17. KOL Views
18. Natural Killer Cell Therapy Market Drivers
19. Natural Killer Cell Therapy Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

List of Top Selling Market Research Reports in 2025

Novel Drug Delivery Devices Market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Psoriasis Vulgaris Market- https://www.delveinsight.com/report-store/chronic-plaque-psoriasis-market
Surgical Energy Instruments Market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Immune Checkpoints Activators Market- https://www.delveinsight.com/report-store/immune-checkpoint-inhibitors-market
Vitreoretinal Surgery Devices Market- https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market
Cystic Fibrosis Market- https://www.delveinsight.com/report-store/cystic-fibrosis-market
Surgical Robotic System Market- https://www.delveinsight.com/report-store/surgical-robotic-system-market
Thrombectomy Devices Market- https://www.delveinsight.com/report-store/neurovascular-thrombectomy-devices-market
Diabetic Wound Market- https://www.delveinsight.com/report-store/diabetic-wounds-market
Indwelling Catheters Market- https://www.delveinsight.com/report-store/urinary-catheters-market
Attention Deficit Hyperactivity Disorder Market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Overactive Bladder Syndrome Market- https://www.delveinsight.com/report-store/underactive-bladder-market
Stem Cell Market- https://www.delveinsight.com/report-store/stem-cell-market
Healthcare Competitive Benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
Thyroid Cancer Market- https://www.delveinsight.com/report-store/thyroid-cancer-market
Antibody Drug Conjugate Market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Surgical Mask & Respirator Market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Total Knee Arthroplasty Market - https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Bone Growth Stimulator Market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Medical Marijuana Market- https://www.delveinsight.com/report-store/medical-marijuana-market-insight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us
Yash Bhardwaj
info@delveinsight.com
https://www.delveinsight.com/

This release was published on openPR.